SAN DIEGO, Sept. 25, 2014 /PRNewswire/ -- Lpath, Inc. (NASDAQ: LPTN) today announced that Scott Pancoast, president and CEO, will present at the 13th Annual BIO Investor Forum on Tuesday, October 7, 2014 at 8:30 a.m. PDT in San Francisco. Mr. Pancoast will provide an update on the company’s lead product candidate, iSONEP, currently in a Phase 2 trial (Nexus) to assess its efficacy for patients with wet age-related macular degeneration, and the ASONEP Phase 2a trial in patients with renal cell carcinoma. He will also discuss additional candidates Lpathomab, an anti-LPA antibody that is expected to enter the clinic in early 2015 for neuropathic pain, and Altepan, an anti-leukotriene antibody that is being studied in models of respiratory and inflammatory disease.
The live webcast presentation and replay will be available in the Investor section of the Lpath website at www.Lpath.com.
About Lpath
San Diego-based Lpath, Inc. (NASDAQ: LPTN), an antibody-platform company, is the category leader in lipid-targeted therapeutics. The company’s ImmuneY2 drug-discovery engine has the unique ability to generate therapeutic antibodies that bind to and inhibit bioactive lipids that contribute to disease. For more information, visit www.Lpath.com.
SOURCE Lpath, Inc.
Help employers find you! Check out all the jobs and post your resume.
